EyePoint's DURAVYU Enters Global Phase 3 Trials for Diabetic Macular Edema
EYPT has more than doubled off its 52-week low of $3.91 on elevated volume (2.1× avg).
Summary
EyePoint, Inc. announced the dosing of the first patients in both its global Phase 3 clinical trials (COMO and CAPRI) for DURAVYU™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME). This milestone signifies a critical advancement in the development of DURAVYU, an investigational sustained-delivery therapy targeting a multi-billion-dollar retinal disease market. The initiation of these pivotal trials, informed by positive Phase 2 results and FDA/EMA alignment, de-risks the program and positions DURAVYU as the only TKI in Phase 3 for DME. This progress is material for a company of EyePoint's size, indicating significant pipeline advancement. Investors will now watch for topline data, which is anticipated in the second half of 2027, as a key future catalyst for the company.
At the time of this announcement, EYPT was trading at $17.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $3.91 to $19.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.